It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37–107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46–303 days). The antibody response was higher in seropositive compared to seronegative participants. In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium; Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
2 Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium
3 Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium
4 Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
5 Department of Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium
6 Department of Internal Medicine, Clinique St-Pierre, Ottignies, Belgium
7 Department of Internal Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium
8 Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
9 Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium; Qualiblood sa, Namur, Belgium